Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICG NIR Imaging in Ovarian Cancer Peritoneal Carcinomatosis
NCT01834469Phase 2Completed
- Sponsor
- Institut Jules Bordet
- Start
- Mar 2013
- Primary completion
- Oct 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of indocyanine green in ovarian carcinoma and peritoneal carcinomatosis (PC), sponsored by Institut Jules Bordet. Primary endpoint: Feasibility study of the (intravenously injected) ICG imaging of tumoral implants at 1 year. Started Mar 2013; status: completed.
02
Drugs
indocyanine green
03
Conditions
ovarian carcinomaperitoneal carcinomatosis (PC)
Beyond the preview
Go deeper on NCT01834469.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01834469.